Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LMWH for Prevention of Thromboembolic Complications After TACE in HCC
NCT02715492Phase 3Unknown
- Start
- Oct 2018
- Primary completion
- Dec 2022
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of enoxaparin in hepatocellular carcinoma (HCC). Primary endpoint: Number of patients with portal vein thrombosis at 3 months. Status: unknown.
02
Drugs
enoxaparin
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT02715492.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02715492.